• Axe Compute sold its Helomics cancer diagnostics lab business to DataMEDS AI in an all-stock transaction dated Sept. 15, 2026.
• Consideration comprised DataMEDS common shares and common share equivalents, leaving Axe Compute with an equity stake in DataMEDS.
• The divestiture completes Axe Compute’s shift from its legacy oncology operations into a pure-play neocloud GPU-as-a-Service platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axe Compute Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006093), on September 17, 2026, and is solely responsible for the information contained therein.